Table 2.
Trials of tipifarnib in combination with chemotherapeutic agents
| Phase | Patient population | Dose-schedules
|
Response rate | |
|---|---|---|---|---|
| (Author) | Tipifarniba | Chemotherapy | ||
| I | New Dx | 300, 400, 600 | etoposide | CR 25% (21/84) |
| Poor risk | 14 vs 21 days | 100, 150, 200 mg | med DFS 9.8 mo | |
| Age ≥ 70 | Days 1–3 and 8–10 | CR med OS 22 mo | ||
| (Karp 2006) | ||||
| I | New Dx | 200–600 | ara-C 100 mg/m2day CI × 7 | CR 41% (9/22) |
| Age ≥ 60 | Days 6–15 | daunorubicin 60 mg/m2/day × 3 | OR 50% (11/22) | |
| (Brandwein 2007) | ||||
| II | New Dx | 300 | ara-C 1.5 g/m2/day CI × 3–4 | CR 69% (70/95) |
| Age 17–61 | idarubicin 12 mg/m2/day | med DFS 17 mo | ||
| (Delmonte 2007) | ||||
amg bid.
Abbreviations: CR, complete remission; CRp, complete remission with incomplete platelet recovery; DFS, disease-free survival; OR, overall response; OS, overall survival; mo, months.